There is no cure for food allergies right now. No treatment can permanently eliminate an allergic response to a food and allow you to eat it freely without concern. But the landscape has shifted significantly in recent years: two FDA-approved treatments can reduce the severity of reactions, oral immunotherapy programs are expanding across children’s hospitals, and several experimental approaches are in clinical trials. The goal of current treatments is desensitization, not a cure, but for many people that distinction still means a dramatically safer daily life.
What “Cure” Actually Means in Allergy Medicine
Researchers draw a sharp line between two outcomes. Desensitization means you can tolerate a food as long as you keep eating small amounts of it regularly. If you stop, the protection fades. Sustained unresponsiveness is closer to what most people picture as a cure: you stop eating the food for weeks or months and still don’t react when you encounter it again. Current treatments reliably achieve desensitization. Sustained unresponsiveness happens in some patients, but it’s inconsistent and unpredictable, so no doctor can promise it.
Children Sometimes Outgrow Food Allergies
The closest thing to a natural cure is outgrowing an allergy, and it happens more often than many parents expect, though the odds depend heavily on the food. About 60 to 80 percent of young children with a milk or egg allergy can eat those foods without a reaction by age 16. Peanut allergy is much more persistent: only about 20 percent of children outgrow it. Tree nut, shellfish, and fish allergies tend to stick around into adulthood as well.
There’s no reliable way to predict which children will outgrow their allergies, though milder reactions and lower levels of allergy-specific antibodies in blood tests are generally favorable signs. Allergists periodically re-test children to check whether the allergy has resolved on its own before considering more intensive treatment.
Oral Immunotherapy: The Most Established Treatment
Oral immunotherapy (OIT) is the most widely used active treatment for food allergies, particularly peanut allergy. The concept is straightforward: you eat tiny, carefully measured amounts of the allergen every day, gradually increasing the dose over months until your immune system tolerates a meaningful quantity.
The process typically involves at least 10 clinic visits spaced about two weeks apart, with the dose roughly doubling at each visit. Between appointments, you take a daily dose at home. For a single food allergy, reaching the maintenance dose usually takes about six months. After that, you continue eating the maintenance dose every day for at least one to three years, with clinic check-ins every three months.
In clinical trials of Palforzia, the only FDA-approved oral immunotherapy product (for peanut allergy in patients ages 4 through 17), about 67 percent of treated children could tolerate 600 milligrams of peanut protein, roughly two peanuts, with no more than mild symptoms. In younger children ages 1 through 3, the success rate was about 74 percent. However, roughly 22 percent of patients dropped out of the treatment, many due to side effects like stomach pain, nausea, or allergic reactions during the buildup phase.
OIT does not mean you can eat peanut butter sandwiches freely. You must keep taking daily doses to maintain protection, and accidental exposures to large amounts can still cause reactions. The goal is to raise your threshold high enough that an accidental bite of something at a restaurant doesn’t become a medical emergency.
Xolair: Protection Across Multiple Foods
In 2024, the FDA approved Xolair (omalizumab) as the first medication for food allergy that works across multiple foods at once. It’s an injection given every two to four weeks, approved for adults and children 1 year and older.
Xolair works differently from immunotherapy. Instead of training your immune system to tolerate a specific food, it blocks IgE, the antibody type that triggers allergic reactions, from attaching to immune cells. With less IgE able to sound the alarm, your threshold for reacting goes up. This makes accidental exposures less dangerous.
The key limitations: Xolair is not a cure. You still need to avoid your allergens. It reduces the risk and severity of reactions from accidental exposure, but it’s not designed to let you intentionally eat foods you’re allergic to. It also requires ongoing injections to maintain its effect. Some allergists use Xolair alongside oral immunotherapy to reduce side effects during the buildup phase.
Skin Patch Immunotherapy
A peanut patch called Viaskin delivers tiny amounts of peanut protein through the skin rather than through the gut. In a phase 3 trial studying peanut-allergic toddlers, 67 percent responded to treatment after one year compared to 33.5 percent on placebo. The treatment effect continued to increase over the following two years, and the safety profile was favorable, with most side effects limited to skin reactions at the patch site.
The patch approach is appealing because it avoids the stomach-related side effects common with oral immunotherapy, and it doesn’t require swallowing measured doses every day. It has not yet received FDA approval, though the manufacturer is actively pursuing it.
Why a True Cure Is So Difficult
Food allergies involve a fundamental misdirection of the immune system. Your body produces IgE antibodies against proteins in foods like peanut, milk, or egg as though they were dangerous invaders. Those antibodies sit on the surface of immune cells throughout your body, primed to trigger inflammation the moment they encounter the food protein again. Reversing this requires not just suppressing the reaction temporarily but retraining the immune system’s memory, which current treatments can only partially achieve.
The immune system has multiple redundant pathways that reinforce allergic responses, which is why desensitization often fades when you stop regular exposure. Researchers are exploring whether manipulating the gut microbiome, the trillions of bacteria in your digestive tract, could offer a more durable reset. Early research has identified clear differences in gut bacteria between allergic and non-allergic individuals, and clinical trials are testing probiotics, prebiotics, and fecal microbiota transplants as potential therapies. Results so far are preliminary, with only a small number of trials studying patients with confirmed food allergies.
Living With Food Allergies Today
Food allergies affect up to 8 percent of children and 10 percent of adults in the United States. For most people, strict avoidance remains the primary strategy, with epinephrine auto-injectors carried for emergencies.
Updated guidelines have made emergency management more practical. Rather than requiring an emergency room visit after every epinephrine dose, current recommendations allow some people to stay home after using epinephrine if their symptoms resolve, they have a second auto-injector available, another person is present, and they live within 30 minutes of a hospital. This shift recognizes that many reactions resolve fully with a single dose.
For families weighing treatment options, the decision depends on the specific allergy, the child’s age, and how much risk accidental exposure poses in daily life. OIT and Xolair don’t eliminate the allergy, but they can widen the margin of safety enough to make school lunches, birthday parties, and restaurant meals less terrifying. That’s not a cure, but for many families it’s a meaningful change in quality of life.